Jump to content

Talk:Osimertinib

Page contents not supported in other languages.
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Lil bklyn (talk | contribs) at 00:28, 28 January 2018 (→‎Nature Magazine as a source). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

EU approval Feb 2016

TAGRISSO™ (OSIMERTINIB) APPROVED IN EU AS FIRST-IN-CLASS TREATMENT FOR PATIENTS WITH EGFR T790M MUTATION-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER refers to two Phase II studies (AURA extension and AURA2) - Rod57 (talk) 02:52, 4 February 2016 (UTC)[reply]

Nature Magazine as a source

Efforts to edit this article are being denied on the premise that Nature magazine is not a reliable souce. It is reliable and fits int he guildlines. — Preceding unsigned comment added by Lil bklyn (talkcontribs) 22:43, 26 January 2018 (UTC)[reply]

Please make sure you sign your posts on talk pages - you do that by typing exactly four tildas at the end -- when you click "save" the Wikipedia software will convert that into links to your user page and talk page, and date stamp it. Also as this evolves please thread your comments, as I have done here. See WP:THREAD.
Please do read WP:MEDRS, especially the WP:MEDDEF section. Not everything published in Nature (or any journal) is OK to use in WP for content about health. Thx Jytdog (talk) 03:56, 27 January 2018 (UTC)[reply]
I read them, and they have been noted. There is no reason to remove anything from Nature Magazing by the standards listed in those policies. The quotes in question are completely legitamate clinical trials and data listed in a reputable journal. I hope we have settled this now.

Lil bklyn (talk) 00:28, 28 January 2018 (UTC)[reply]